Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.

Postmus I, Johnson PC, Trompet S, de Craen AJ, Slagboom PE, Devlin JJ, Shiffman D, Sacks FM, Kearney PM, Stott DJ, Buckley BM, Sattar N, Ford I, Westendorp RG, Jukema JW.

Atherosclerosis. 2014 Jul;235(1):58-64. doi: 10.1016/j.atherosclerosis.2014.04.009. Epub 2014 Apr 26.

PMID:
24816038
2.

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.

Trompet S, de Craen AJ, Postmus I, Ford I, Sattar N, Caslake M, Stott DJ, Buckley BM, Sacks F, Devlin JJ, Slagboom PE, Westendorp RG, Jukema JW; PROSPER Study Group.

BMC Med Genet. 2011 Oct 6;12:131. doi: 10.1186/1471-2350-12-131.

3.

Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.

Shiffman D, Trompet S, Louie JZ, Rowland CM, Catanese JJ, Iakoubova OA, Kirchgessner TG, Westendorp RG, de Craen AJ, Slagboom PE, Buckley BM, Stott DJ, Sattar N, Devlin JJ, Packard CJ, Ford I, Sacks FM, Jukema JW.

PLoS One. 2012;7(5):e38240. doi: 10.1371/journal.pone.0038240. Epub 2012 May 30.

4.

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.

Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J, Packard C, Buckley BM, Schaefer EJ.

Atherosclerosis. 2012 Feb;220(2):456-62. doi: 10.1016/j.atherosclerosis.2011.11.037. Epub 2011 Dec 7.

PMID:
22192511
5.

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.

Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Westendorp RG, de Craen AJ, Buckley BM, Ordovas JM, Schaefer EJ; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators.

Atherosclerosis. 2008 Sep;200(1):109-14. doi: 10.1016/j.atherosclerosis.2007.12.004. Epub 2008 Feb 7.

6.

Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.

Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J, Packard C, Buckley BM, Schaefer EJ.

Atherosclerosis. 2012 Feb;220(2):413-7. doi: 10.1016/j.atherosclerosis.2011.09.028. Epub 2011 Sep 21.

PMID:
22189199
7.

Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER Study Group.

Circulation. 2005 Nov 15;112(20):3058-65. Epub 2005 Nov 7.

8.

Genome-wide association of lipid-lowering response to statins in combined study populations.

Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, Li X, Wilke RA, Rieder MJ, Williams PT, Ridker PM, Chatterjee A, Rotter JI, Nickerson DA, Stephens M, Krauss RM.

PLoS One. 2010 Mar 22;5(3):e9763. doi: 10.1371/journal.pone.0009763.

9.

Pharmacogenetic study of statin therapy and cholesterol reduction.

Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM.

JAMA. 2004 Jun 16;291(23):2821-7.

PMID:
15199031
10.

Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.

Postmus I, Verschuren JJ, de Craen AJ, Slagboom PE, Westendorp RG, Jukema JW, Trompet S.

Pharmacogenomics. 2012 May;13(7):831-40. doi: 10.2217/pgs.12.25. Review.

PMID:
22594514
11.
12.

Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.

Drewes YM, Poortvliet RK, Blom JW, de Ruijter W, Westendorp RG, Stott DJ, Blom HJ, Ford I, Sattar N, Wouter Jukema J, Assendelft WJ, de Craen AJ, Gussekloo J.

J Am Geriatr Soc. 2014 Feb;62(2):213-21. doi: 10.1111/jgs.12660. Epub 2014 Jan 21.

13.

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.

Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS.

Circ Cardiovasc Genet. 2008 Dec;1(2):100-6. doi: 10.1161/CIRCGENETICS.108.795013. Epub 2008 Dec 9.

14.

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.

Chu AY, Guilianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):58-65. doi: 10.1161/CIRCGENETICS.111.961847. Epub 2012 Jan 9.

15.

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.

Nishiwaki M, Ikewaki K, Ayaori M, Mizuno K, Ohashi Y, Ohsuzu F, Ishikawa T, Nakamura H; MEGA Study Group.

J Cardiol. 2013 Mar;61(3):196-200. doi: 10.1016/j.jjcc.2012.10.005. Epub 2012 Dec 21.

16.

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).

Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA; CARDS, ASCOT, and PROSPER Investigators.

J Lipid Res. 2012 May;53(5):1000-11. doi: 10.1194/jlr.P021113. Epub 2012 Feb 24.

17.

A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).

Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, Orimo H.

J Atheroscler Thromb. 2001;8(2):33-44. Erratum in: J Atheroscler Thromb 2001;8(3):following 100.

PMID:
11770708
18.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators.

JAMA. 2001 Jul 4;286(1):64-70.

PMID:
11434828
19.

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.

Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ; CHARISMA Investigators.

J Am Coll Cardiol. 2007 Jul 24;50(4):291-5. Epub 2007 Jul 10.

20.

Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Poortvliet RK, Ford I, Lloyd SM, Sattar N, Mooijaart SP, de Craen AJ, Westendorp RG, Jukema JW, Packard CJ, Gussekloo J, de Ruijter W, Stott DJ.

PLoS One. 2012;7(12):e52438. doi: 10.1371/journal.pone.0052438. Epub 2012 Dec 20.

Items per page

Supplemental Content

Write to the Help Desk